Inventor · disambiguated record
Alison Crawford
Also filed as: CRAWFORD ALISON
11 granted patents·6 pending applications·153 citations·filing 2016–2025
90Inventor score
Files withREGENERON PHARMA17
Top patents by PatentIndex Score
17 records- 0197US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0297US10179819B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2016·Granted Jan 15, 2019·25 cites·12 claims
- 0396US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 0495US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 0595US11155633B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2018·Granted Oct 26, 2021·9 cites·24 claims
- 0694US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 0793US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 0893US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 0981US11254752B2Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodiesREGENERON PHARMA·Filed 2019·Granted Feb 22, 2022·2 cites·22 claims
- 1081US2025282891A1Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1176US12344677B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 1, 2025·0 cites·28 claims
- 1270US2025042999A1Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1368US2025114469A1METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINEREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1468US2023279113A1Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1564US2025340668A1Multispecific binding molecule proproteins and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1660US12091460B2Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulationREGENERON PHARMA·Filed 2020·Granted Sep 17, 2024·0 cites·17 claims
- 1746US2020399372A1Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulationREGENERON PHARMA·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alison Crawford files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →